Blum Robert I 4

What Happened

Robert I. Blum, President & CEO and a Director of Cytokinetics (CYTK), received annual equity awards reported on March 17, 2026 for transactions dated March 15, 2026. The filing shows:

• 75,258 restricted stock units (RSUs) granted (convert 1:1 to common shares);
• 113,529 derivative awards (1,665 and 111,864 units) reported as acquisitions of derivative securities, consistent with stock option awards. All awards were reported with an acquisition price of $0.00 (typical for grants/awards). These are compensation grants (not open‑market purchases or sales).

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (filed within the typical 2-business‑day Form 4 window).
• Reported amounts: 75,258 RSUs; 1,665 and 111,864 derivative units (total 113,529 derivative awards). Acquisition price reported as $0.00.
• Vesting: RSUs vest 40% after 1 year, 40% after 2 years, and 20% after 3 years (per F1). Stock options vest in 48 equal monthly installments (per F4/F5).
• Shares owned after the transaction are not specified in the provided summary of the filing.
• Footnotes: F1 describes RSU vesting; F4/F5 describe option vesting; F2/F3 indicate certain shares are held in family trusts.

Context

• These entries are awards (code A) — compensation grants to an executive — and not sales or purchases in the open market. Options/derivative awards are not exercises; they represent the right to acquire shares in the future subject to vesting.
• Awards like RSUs and options are routine executive compensation and do not by themselves indicate a buy or sell signal.